Krystal Biotech (KRYS) Study Result summary
Event summary combining transcript, slides, and related documents.
Study Result summary
8 Jul, 2026Program Overview and Technology
KB301 is a gene therapy candidate delivering COL3A1 via a non-integrating HSV-1 vector to restore type III collagen, targeting skin rejuvenation and reversing age-related collagen decline.
The platform enables delivery of multiple genes, aiming to rebuild skin structure and improve appearance, and supports future pipeline expansion targeting other extracellular matrix proteins.
Jeune Aesthetics, a subsidiary of Krystal Biotech, is focused on clinical development, leveraging Krystal's manufacturing and regulatory expertise.
Study Design and Objectives
KB301 was evaluated in PEARL-I, a multicenter, open-label, split-body study for dynamic wrinkles of the décolleté and lateral canthal lines at rest in adults up to 75 years, with no recent skin treatments in target areas.
Key objectives included safety and preliminary efficacy, assessed by both investigators and subjects using GAIS and SSQ.
Cohorts III and IV focused on lateral canthal lines at rest and dynamic wrinkles of the décolleté, both areas lacking approved injectables.
Dosing regimens included both low and high dose KB301, with various administration techniques explored.
Efficacy and Durability Results
KB301 showed clinically meaningful improvements: in the décolleté, 94% of subjects had at least a one-point improvement at two months, with 28% achieving a two-point gain; in lateral canthal lines, over 90% improved by at least one GAIS point at one month, and 75% at two months.
100% of subjects in both cohorts were responders by GAIS at two months in some studies, with improvements increasing over time.
Improvements extended to skin texture, hydration, radiance, elasticity, and crepiness, with investigator-reported improvements in up to 94% of décolleté subjects.
Subject satisfaction scores remained elevated for at least 7-9 months after last dose in earlier cohorts, with durability studies showing sustained efficacy up to nine months.
Before-and-after images demonstrated visible reduction in wrinkles and improved skin appearance.
Latest events from Krystal Biotech
- KB407 achieved robust, safe CFTR delivery and expression in CF lungs, enabling registrational trials.KRYS
Study Update9 Jul 2026 - KB408 and KB407 show strong safety, efficient lung gene delivery, and support for accelerated development.KRYS
Status Update8 Jul 2026 - Robust revenue, global expansion, and a deep gene therapy pipeline drive growth and innovation.KRYS
Corporate presentation25 May 2026 - Global expansion and pivotal pipeline progress set the stage for a transformative 12-24 months.KRYS
Bank of America Global Healthcare Conference 202619 May 2026 - All proposals, including director elections and compensation policies, were approved.KRYS
AGM 202615 May 2026 - Q1 2026 revenue and profit surged, with strong margins and major clinical milestones ahead.KRYS
Q1 20264 May 2026 - Global launches and pipeline advances drive growth, with key milestones expected in 2026.KRYS
44th Annual J.P. Morgan Healthcare Conference15 Apr 2026 - Proxy covers director elections, auditor ratification, pay, and new director compensation policy.KRYS
Proxy filing3 Apr 2026 - Key votes include director elections, auditor ratification, and compensation approvals.KRYS
Proxy filing3 Apr 2026